scholarly journals Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response

2009 ◽  
Vol 284 (27) ◽  
pp. 18085-18095 ◽  
Author(s):  
Yong-Wei Zhang ◽  
Tamara L. Jones ◽  
Scott E. Martin ◽  
Natasha J. Caplen ◽  
Yves Pommier
2011 ◽  
Vol 82 (11) ◽  
pp. 1604-1618 ◽  
Author(s):  
Benny J. Evison ◽  
Mile Pastuovic ◽  
Rebecca A. Bilardi ◽  
Robert A. Forrest ◽  
Paul P. Pumuye ◽  
...  

2003 ◽  
Vol 278 (23) ◽  
pp. 20480-20489 ◽  
Author(s):  
Jinwoo Ahn ◽  
Marshall Urist ◽  
Carol Prives

2009 ◽  
Vol 8 (1) ◽  
pp. 45-54 ◽  
Author(s):  
Leslie A. Parsels ◽  
Meredith A. Morgan ◽  
Daria M. Tanska ◽  
Joshua D. Parsels ◽  
Brian D. Palmer ◽  
...  

2007 ◽  
Vol 28 (2) ◽  
pp. 752-771 ◽  
Author(s):  
Stela S. Palii ◽  
Beth O. Van Emburgh ◽  
Umesh T. Sankpal ◽  
Kevin D. Brown ◽  
Keith D. Robertson

ABSTRACT Genome-wide DNA methylation patterns are frequently deregulated in cancer. There is considerable interest in targeting the methylation machinery in tumor cells using nucleoside analogs of cytosine, such as 5-aza-2′-deoxycytidine (5-azadC). 5-azadC exerts its antitumor effects by reactivation of aberrantly hypermethylated growth regulatory genes and cytoxicity resulting from DNA damage. We sought to better characterize the DNA damage response of tumor cells to 5-azadC and the role of DNA methyltransferases 1 and 3B (DNMT1 and DNMT3B, respectively) in modulating this process. We demonstrate that 5-azadC treatment results in growth inhibition and G2 arrest—hallmarks of a DNA damage response. 5-azadC treatment led to formation of DNA double-strand breaks, as monitored by formation of γ-H2AX foci and comet assay, in an ATM (ataxia-telangiectasia mutated)-dependent manner, and this damage was repaired following drug removal. Further analysis revealed activation of key strand break repair proteins including ATM, ATR (ATM-Rad3-related), checkpoint kinase 1 (CHK1), BRCA1, NBS1, and RAD51 by Western blotting and immunofluorescence. Significantly, DNMT1-deficient cells demonstrated profound defects in these responses, including complete lack of γ-H2AX induction and blunted p53 and CHK1 activation, while DNMT3B-deficient cells generally showed mild defects. We identified a novel interaction between DNMT1 and checkpoint kinase CHK1 and showed that the defective damage response in DNMT1-deficient cells is at least in part due to altered CHK1 subcellular localization. This study therefore greatly enhances our understanding of the mechanisms underlying 5-azadC cytotoxicity and reveals novel functions for DNMT1 as a component of the cellular response to DNA damage, which may help optimize patient responses to this agent in the future.


PLoS Genetics ◽  
2013 ◽  
Vol 9 (4) ◽  
pp. e1003310 ◽  
Author(s):  
Carla Manuela Abreu ◽  
Ramesh Kumar ◽  
Danielle Hamilton ◽  
Andrew William Dawdy ◽  
Kevin Creavin ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1913 ◽  
Author(s):  
Makoto Takeuchi ◽  
Michihiro Tanikawa ◽  
Kazunori Nagasaka ◽  
Katsutoshi Oda ◽  
Yoshiko Kawata ◽  
...  

While the incidence of endometrial cancer continues to rise, the therapeutic options remain limited for advanced or recurrent cases, and most cases are resistant to therapy. The anti-tumor effect of many chemotherapeutic drugs and radiotherapy depends on the induction of DNA damage in cancer cells; thus, activation of DNA damage response (DDR) pathways is considered an important factor affecting resistance to therapy. When some DDR pathways are inactivated, inhibition of other DDR pathways can induce cancer-specific synthetic lethality. Therefore, DDR pathways are considered as promising candidates for molecular-targeted therapy for cancer. The crosstalking ataxia telangiectasia mutated and Rad3 related and checkpoint kinase 1 (ATR-Chk1) and ataxia telangiectasia mutated and Rad3 related and checkpoint kinase 2 (ATM-Chk2) pathways are the main pathways of DNA damage response. In this study, we investigated the anti-tumor effect of inhibitors of these pathways in vitro by assessing the effect of the combination of ATM or ATR inhibitors and conventional DNA-damaging therapy (doxorubicin (DXR), cisplatin (CDDP), and irradiation) on endometrial cancer cells. Both the inhibitors enhanced the sensitivity of cells to DXR, CDDP, and irradiation. Moreover, the combination of ATR and Chk1 inhibitors induced DNA damage in endometrial cancer cells and inhibited cell proliferation synergistically. Therefore, these molecular therapies targeting DNA damage response pathways are promising new treatment strategies for endometrial cancer.


2007 ◽  
Vol 46 (12) ◽  
pp. 1061-1068 ◽  
Author(s):  
Kriste A. Lewis ◽  
Jamie Bakkum-Gamez ◽  
Ralitsa Loewen ◽  
Amy J. French ◽  
Stephen N. Thibodeau ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document